Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Alpha Tau Medical Ltd ( (DRTS) ).
On February 24, 2026, Alpha Tau Medical Ltd. announced that Japan’s Ministry of Health, Labour and Welfare granted Shonin marketing approval for its Alpha DaRT therapy to treat unresectable locally advanced or locally recurrent head and neck cancer. The decision follows rigorous review by Japan’s Pharmaceuticals and Medical Devices Agency and marks the first approval of Alpha DaRT outside Israel, signaling regulatory validation of this first-in-kind intratumoral alpha-radiation platform.
As a condition of approval, Alpha Tau will conduct a post‑market surveillance study of 66 patients at five leading Japanese centers to further assess safety and performance in real-world practice. Backed by longstanding collaboration with distributor HekaBio and strong support from Japanese medical societies and clinicians, the early Japanese authorization—preceding similar decisions in the U.S. and Europe—could enhance Alpha Tau’s standing in global oncology and accelerate clinical adoption in head and neck cancer.
The most recent analyst rating on (DRTS) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
Overall score is held down primarily by very weak fundamentals (no revenue, ongoing losses, and persistent cash burn), with only partial support from an improved balance sheet. Technicals are a near-term positive with strong trend strength, but overbought momentum indicators add downside risk. Valuation remains unattractive/unclear due to negative earnings and no dividend yield.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Founded in 2016 and based in Israel, Alpha Tau Medical Ltd. is an oncology therapeutics company focused on researching, developing and commercializing Alpha DaRT, a diffusing alpha-emitters radiation therapy for solid tumors. The technology uses intratumoral delivery of radium-224 sources to provide highly localized alpha-irradiation aimed at destroying tumors while sparing surrounding healthy tissue.
Average Trading Volume: 328,186
Technical Sentiment Signal: Buy
Current Market Cap: $624.1M
See more data about DRTS stock on TipRanks’ Stock Analysis page.